Chronic fatigue can be a frequent complaint about patients suffering from immune-mediated diseases. Artvigil is a drug that acts as a psychostimulant approved by the Food and Drug Administration in 1998 and is used to treat chronic daytime sleepiness and narcolepsy.
It is commonly recommended off-label for ADHD chronic fatigue, mood enhancement cognitive enhancement, and mood-boosting.
All of it is related to dopamine, as well as other neurochemical messengers.
Dopamine, a key neurotransmitter to many brain functions, controls mood, cognition, and behavior. It is now clear that dopamine is an immediate connection to the well-being and health that is the immunity system.
- Dopamine-related actions: Artvigil’s wakefulness is caused by dopamine D1 and D2 receptors. Buy online Artvigil 150 mg is highly affine for its DAT (dopamine transporter). Dopamine levels will increase in the case of blocking this DAT signal. Dopamine transporter (DAT) is a neurotransmitter that regulates the temporal and spatial dynamics of dopamine neurotransmission. It also drives the reuptake of extracellular transmitters to presynaptic cells.
- Artvigil actions: Artvigil also affects the central norepinephrine system (NE). Artvigil binds to the norepinephrine transporter (NET) and blocks the reuptake. This prevents sleep-related activation of the ventrolateral posterior nucleus (VLPO), a subset of sleep-active neurons located in the hypothalamus of rats. It is believed that it inhibits the main ascending monoaminergic awaken systems.
It is becoming increasingly clear that Artvigil is more than reducing fatigue.
Other research results that are strong support ongoing research into various applications in neurological disorders are:
- Cognitive Enhancement
Artvigil is effective in improving working memory, and attention in addition to recognition memory and other cognitive abilities. Artvigil has been proven to boost cognition in people who have schizophrenia and in adolescents with ADHD. The power of Artvigil to promote neural development in the hippocampal region could be due to this effect. This was confirmed in rats and lab mice.
- Reduction in Neuroinflammation.
Artvigil is a potent blocker of microglial activation and, consequently, the in-situ production of pro-inflammatory mediators. Artvigil is an attractive therapeutic alternative for neurodegenerative disorders where neuroinflammation plays a significant role.
- Potential use in neurodegenerative diseases
Fuxe and his team have been the first people to show that Artvigil can treat Parkinson’s disease.
Artvigil is frequently given to people suffering from MS. This research has proven that the benefits of Artvigil’s therapy are closely connected to its anti-inflammatory properties.
Mice models show the mechanism
- The frequency of Th-1 cells is reduced.
- A dramatic drop in interferon-g levels.
- EAE symptoms are not like those suffering from experimental autoimmune encephalitis (EAE).
These results show that Artvigil may be more than a simple way to reduce fatigue in patients with neurological/autoimmune conditions.
Artvigil uses to stimulate immune modulation.
The immunomodulating effects of Artvigil are extensively researched. Although it causes inflammation in the immune cells of the peripheral of mice that are naive by activating the IFN-mediated immune system and has been proven that it is anti-inflammatory, it has been demonstrated to be anti-inflammatory in animals suffering from inflammatory diseases. Artvigil is believed to improve the blood-brain barrier (BBB). This could happen by direct or indirect alteration of the functioning of the circumventricular organs, such as the choroid. This is because it may alter the permeability to immune cells as well as other mediators of inflammation.
